cas 1853338-91-6|| where to buy 5-(3,3-DiMethylcyclobutyl)-1H-pyrazol-3-ylaMine

Nom du produit:5-(3,3-DiMethylcyclobutyl)-1H-pyrazol-3-ylaMine

IUPAC Name:5-(3,3-dimethylcyclobutyl)-1H-pyrazol-3-amine

Unité d'emballage	Stock disponible	Prix($)
CM107408-100mg	in stock	Ÿƴȅ
CM107408-250mg	in stock	ƴƐƐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1853338-91-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1853338-91-6; Formule moléculaire:C9H15N3; Point de fusion:-; Code SMILES:NC1=NNC(C2CC(C)(C)C2)=C1; Densité:

: Numéro de catalogue:CM107408; Poids moléculaire:165.24; Point d'ébullition:; N° Mdl:; Stockage:

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Cyclobutanes; The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.